Adding a collagen–polymethyl methacrylate scaffold to volar fibroblast therapy did not substantially enhance the development of palm- and sole-like skin characteristics but induced distinct stromal remodeling and immune cell recruitment.
Researchers enrolled 10 healthy volunteers to evaluate whether a collagen–polymethyl methacrylate (PMMA) scaffold could enhance the effects of transplanted volar fibroblasts in nonvolar skin. Participants received scaffold injections followed by autologous fibroblasts obtained from the sole or scalp, or a vehicle control, at designated thigh sites. Each fibroblast treatment consisted of 10 million cells administered across 3 sessions. Tissue responses were assessed at 2 and 5 months and compared with those of a previously studied cohort treated with fibroblast therapy without the scaffold.
The researchers evaluated skin firmness, epidermal thickness, and dermal architecture using durometry, optical coherence tomography, and histological analysis. Additional assessments included papillary elastin, collagen content and fiber organization, and changes in stromal and immune cell populations. Single-cell RNA sequencing and spatial transcriptomics were used to characterize cellular and molecular responses to scaffold administration.
Sole fibroblast treatment combined with collagen/PMMA was associated with statistically significant increases in skin firmness, epidermal thickness, papillary elastin, collagen content, and collagen fiber length compared with vehicle-treated sites. These findings indicated that volar fibroblasts retained their capacity to induce selected palm- and sole-like structural characteristics in the presence of the scaffold.
However, the scaffold did not significantly enhance fibroblast-associated epidermal thickening compared with fibroblast therapy alone. A mixed-effects analysis that included the historical comparison cohort found no statistically significant interaction between scaffold administration and fibroblast treatment. The scaffold also had no statistically significant independent effect on epidermal thickness.
Optical coherence tomography identified epidermal thickening at fibroblast-treated sites, with differences more apparent at 5 months than at 2 months. Histological analyses demonstrated increased papillary elastin and collagen remodeling following sole fibroblast transplantation. However, these changes did not establish an additional volarizing benefit from the scaffold.
Molecular analyses revealed a separate tissue response associated with collagen/PMMA administration. Researchers identified 1,824 shared differentially expressed genes across scaffold-related comparisons, including genes involved in extracellular matrix organization, elastic fiber assembly, angiogenesis, and immune responses.
Spatial transcriptomic analysis showed increased fibroblast, immune, and endothelial cell populations in scaffold-treated tissue, including sites receiving vehicle rather than transplanted fibroblasts. These findings indicated that scaffold-associated remodeling occurred independently of which fibroblasts we injected.
Histological examination identified persistent PMMA microspheres surrounded by mononuclear inflammatory and histiocyte-like cells, consistent with a localized foreign body response. Multinucleated foreign body giant cells were not prominent. Although transcriptomic analyses identified remodeling-associated and potentially profibrotic cellular programs, these results did not establish progressive fibrosis or granulomatous inflammation.
The study was limited by its small sample size, exploratory analyses, and use of a historical fibroblast-only comparison cohort. Several structural measurements involved 7 participants, while collagen assessments at 5 months involved 3 participants. Single-cell RNA sequencing included tissue from 1 participant per treatment cohort, and spatial transcriptomic analyses included 2 biological replicates per condition. Follow-up was limited to 5 months, and the researchers could not distinguish the separate effects of collagen and PMMA or directly track transplanted fibroblasts. The study also did not evaluate pressure tolerance, friction resistance, or protection against skin breakdown.
“Future studies will be required to determine whether the resulting increase in skin thickness and firmness provides functional benefit without progressive fibrosis or chronic inflammation,” wrote lead study author Sam S. Lee, PhD, of Johns Hopkins University School of Medicine, Baltimore, and colleagues.
Luis A. Garza reported unrelated institutional funding and licensing royalties from Sun Pharma Advanced Research Company, as well as honoraria and travel support from Lilly and Novartis. The remaining authors reported no conflicts of interest.
